Biotech News

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Apellis Pharmaceuticals (APLS)Apellis Pharmaceuticals2026-06-25 13:46 ESTEarnings

Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of

Open original release

Related news

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Apellis Pharmaceuticals

Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States